Search Within

Michael Gong

Refine Results
Formats
  1. Journal Article (7)
  2. Meeting Abstract (1)
Groups
  1. Center for Hematologic Malignancies (7)
  2. Molecular Pharmacology and Chemistry Program Faculty (7)
  3. Sloan Kettering Institute Faculty (7)
  4. Hematologic Malignancies Research (4)
  5. Adult Leukemia (3)
  6. Hematologic Malignancies Research (3)

More Groups

People
  1. Michel Sadelain (7)
  2. Isabelle Riviere (3)
  3. Jean-Baptiste Latouche (3)
  4. Renier Brentjens (3)
  5. Clay Lyddane (2)
  6. Elmer Santos (2)

More People

Years
  1. 2005 (1)
  2. 2003 (1)
  3. 2001 (2)
  4. 2000 (2)
  5. 1999 (2)
Publications
  1. Molecular Urology (2)
  2. Blood (1)
  3. Cancer Research (1)
  4. Cancer and Metastasis Reviews (1)
  5. Critical Reviews in Immunology (1)
  6. Nature Medicine (1)

More Publications

Publishers
  1. Mary Ann Liebert, Inc (2)
  2. American Association for Cancer Research (1)
  3. American Society of Hematology (1)
  4. Begell House, Inc (1)
  5. Elsevier Science Inc. (1)
  6. Nature Publishing Group (1)

More Publishers

Results (8)

Export to EndNote | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Targeted elimination of prostate cancer by genetically directed human T lymphocytes
    Journal Article

    Gade, T. P. F.; Hassen, W.; Santos, E.; Gunset, G.; Saudemont, A.; Gong, M. C.; Brentjens, R.; Zhong, X. S.; Stephan, M.; Stefanski, J.; more...
    Cancer Research (2005)

    Fulltext@MSK | Save
  • Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15
    Journal Article

    Brentjens, R. J.; Latouche, J. B.; Santos, E.; Marti, F.; Gong, M. C.; Lyddane, C.; King, P. D.; Larson, S.; Weiss, M.; RivieĢ€re, I.; more...
    Nature Medicine (2003)

    Fulltext@MSK | Save
  • Long term survival of SCID-beige mice bearing Raji cell tumors after intravenous treatment with human T cells genetically modified to recognize the CD19 antigen
    Meeting Abstract

    Brentjens, R. J.; Gong, M. C.; Latouche, J. B.; Riviere, I.; Sadelain, M.
    Blood (2001)

    Fulltext@MSK | Save
  • A unique folate hydrolase, prostate-specific membrane antigen (PSMA): A target for immunotherapy?
    Journal Article

    Tasch, J.; Gong, M.; Sadelain, M.; Heston, W. D. W.
    Critical Reviews in Immunology (2001)

    Fulltext@MSK | Save
  • Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy
    Journal Article

    Gong, M. C.; Chang, S. S.; Watt, F.; O'keefe, D. S.; Bacich, D. J.; Uchida, A.; Bander, N. H.; Reuter, V. E.; Gaudin, P. B.; Molloy, P. L.; more...
    Molecular Urology (2000)

    Fulltext@MSK | Save
  • Introduction - Translational research trends: Urologic gene therapy
    Journal Article

    Gong, M. C.; Fair, W. R.
    Molecular Urology (2000)

    Fulltext@MSK | Save
  • Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen
    Journal Article

    Gong, M. C.; Latouche, J. B.; Krause, A.; Heston, W. D. W.; Bander, N. H.; Sadelain, M.
    NeoPlasia (1999)

    Fulltext@MSK | Save
  • Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers
    Journal Article

    Gong, M. C.; Chang, S. S.; Sadelain, M.; Bander, N. H.; Heston, W. D. W.
    Cancer and Metastasis Reviews (1999)

    Fulltext@MSK | Save